Product Name | FK506 |
Description |
FKBP inhibitor |
Purity | >98% |
CAS No. | 104987-11-3 |
Molecular Formula | C44H69HO12 |
Molecular Weight | 804.02 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble to 100 mM in ethanol, and to 100 mM in DMSO |
Source | Synthetic |
Appearance | White Solid |
SMILES | CCC(C)(C)C(=O)C(=O)N1CCCC1C(=O)OCCCC2=CN=CC=C2 |
InChI | InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)4 |
InChIKey | QJJXYPPXXYFBGM-LFZNUXCKSA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection Hazard Phrases: H301 Precautionary Phrases: P301 + P310 |
Cite This Product | FK506 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-214) |
Alternative Names | 3-(3-Pyridinyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)prolinate, Tacrolimus, Fujimycin |
Research Areas | Apoptosis, Cancer |
PubChem ID | 445643 |
Scientific Background | FK506 or Fujimycin or Tacrolimus, is an immunosuppressant. It is mainly used after allogeneic organ transplants, but can also be used topically in the treatment of eczema, uveitis and vitiligo (1). It is a macrolide that prevents the dephosphorylation of NF-AT. It reduces peptidyl-prolyl isomerase activity by binding to FKBP12 creating a new complex that interacts with and inhibits calcineurin (2, 3). |
References |
1. Nanette B., et al. (2004) J Am Acad Derm. 51(5): 760-766. 2. Ganong W.F., Review of Medical Physiology (22nd ed.) Lange Medical Books. P.530 3. Liu J. Lane W., Friedman J, Weissman I and Schreiber S. (1991) Cell. 66(4): 807-815 |
Reviews
There are no reviews yet.